Skip to main content
. 2019 Dec 20;10:1515. doi: 10.3389/fphar.2019.01515

Figure 5.

Figure 5

Safety evaluation of chronic FGF1 administration. (A, B) Evidence of liver injury as determined by serum activities of liver enzymes Alanine transaminase and aspartate transaminase (ALT and AST). (CE) Real-time polymerase chain reaction (RT-PCR) analysis of hepatic mRNA levels of the proliferation markers including Ki-67, AFP, and PCNA in C57BL/6J mice after chronic treatment, data was normalized to actin mRNA levels and expressed as fold change relative to control group (PBS-treated mice) (F) immune-histochemical staining using PCNA. Data are presented as mean ± SEM; *P < 0.05; ***P < 0.001; versus control group; n = 8.